|
Sep 24
|
Insiders Snap Up These 2 ‘Strong Buy’ Stocks
|
|
Sep 3
|
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
|
|
Aug 5
|
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
|
|
Jul 29
|
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
|
|
Jul 26
|
Burger King Parent Company and More Stocks See Action From Activist Investors
|
|
Jun 21
|
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
|
|
May 30
|
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
|
|
May 13
|
Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections
|
|
May 13
|
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
|
|
May 8
|
Terns Pharmaceuticals Announces Leadership Changes
|
|
May 7
|
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
|
|
Apr 29
|
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
|
|
Apr 14
|
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
|
|
Apr 10
|
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
|
|
Mar 14
|
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
|
|
Mar 11
|
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
|
|
Mar 7
|
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
|
|
Nov 29
|
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
|
|
Nov 27
|
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
|
|
Jul 5
|
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
|